QTRX

EX-99.1

2 ex991-qtrxx20260331.htm

EX-99.1

Document

Exhibit 99.1

Quanterix Releases Financial Results for the First Quarter of 2026

Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities

Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness

BILLERICA, Mass. – May 6, 2026 - Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026.

“We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition,” said Everett Cunningham, President & CEO of Quanterix. “As part of this process, we are focusing our investment into areas that will benefit our commercial effectiveness and drive improved operating results in 2026 and beyond. Additionally, our Alzheimer’s diagnostics business continues its rapid growth with several key milestones expected in the second half of this year, including the completion of three clinical utility studies and a decision from the FDA on our 510(k) application.”

First Quarter Financial Highlights

•Revenue of $36.4 million, an increase of 20% compared to $30.3 million in the prior year.

•GAAP gross margin of 42.7%, as compared to 48.9% in the prior year. Adjusted gross margin (non-GAAP) of 50.9% as compared to 49.7% in the prior year. Prior year margins are updated to reflect a change in accounting policy in Q1’26 related to shipping and handling costs. Shipping and handling costs for product sales are now recorded in cost of product revenue in the Company’s GAAP financials.

•Adjusted EBITDA (non-GAAP) loss of $9.8 million, compared to a loss of $11.3 million in the prior year.

•The Company ended the first quarter with $102.6 million of cash, cash equivalents, marketable securities, and restricted cash. Adjusted cash usage, after accounting for one-time deal and employee separation costs of $4.2 million, was $14.7 million in the first quarter, an increase from the fourth quarter of 2025 driven by seasonally higher payments.

Operational and Business Highlights

•Announced a collaboration with Tempus AI to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer’s disease. Through the agreement, Tempus AI will build a care gap program for Alzheimer’s disease blood-based biomarker testing, with Quanterix’s LucentAD® Complete multi-biomarker blood test becoming available for neurologists to order on the Tempus clinical ordering platform.

•Announced a diagnostics collaboration with Life Line Screening (LLS), a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the collaboration, Life Line Screening will offer Quanterix’s Lucent Diagnostics non-invasive blood-based biomarker test for p-tau 217 nationally.

•Selected as a Co-Investigator institution in the PD-BUILD program, part of the Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network (CRN) 2026 expansion, supported by The Michael J. Fox Foundation (MJFF). This multi-year grant brings together leading institutions across academia and industry to develop and deploy high-quality biomarker tools aimed at enabling earlier detection, improved patient stratification, and more effective monitoring of Parkinson’s disease in clinical research.

•Quanterix’s newly launched PhenoCode™ Discovery IO60 panel won silver at the Edison Awards. This award-winning product enables simultaneous visualization of 60 key markers across immune cell types, checkpoints, and tumor-specific pathways.

•Simoa® Ultra-Sensitive Immunoassay launched 3 new assays - mammalian GFAP advantage plus, IL12p70 advantage plus and IL17F advantage plus.

•The Accelerator Service Lab announced two new ADC lung cancer panels for Akoya PhenoImager™ HT at the American Association for Cancer Research(AACR) 2026 annual meeting. Building on the ADC breast cancer panel debuted at the AACR 2025 annual meeting, both panels are available today as a fully managed service.

2026 Business Outlook

Quanterix is reaffirming its guidance for 2026. The Company expects revenues of $169 to $174 million, which assumes no underlying improvement in the academic or pharmaceutical end markets. Quanterix anticipates GAAP gross margin of 41% to 45%, and adjusted gross margin (non-GAAP) of 49% to 53%.

In the first quarter, Quanterix changed its accounting policy for classifying shipping and handling costs for product sales to record them within gross margin. Historically, these costs were recorded in selling, general and administrative expenses. This reclassification is reflected in the Company’s GAAP guidance range, but there is no change to the non-GAAP margin expectation.

Quanterix continues to antici

qtrx-20260302Quanterix Corpfalse000150327400015032742026-03-022026-03-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026

QUANTERIX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware001-3831920-8957988 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

900 Middlesex Turnpike

Billerica, MA 01821 (Address of principal executive offices) (Zip Code)

(617) 301-9400 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, $0.001 par value per shareQTRXThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging Growth Company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition. On March 2, 2026, Quanterix Corporation (“Quanterix”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025 (the “Earnings Release”). A copy of the Earnings Release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits. (d)Exhibits

Exhibit No.Description 99.1Earnings Release dated March 2, 2026

99.2Slides from March 2, 2026 Earnings Call

104Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

QUANTERIX CORPORATION

By:/s/ VANDANA SRIRAM Vandana Sriram Chief Financial Officer

Date: March 2, 2026

qtrx-20260108Quanterix Corpfalse000150327400015032742026-01-082026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026

QUANTERIX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware001-3831920-8957988 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

900 Middlesex Turnpike Billerica, MA 01821 (Address of principal executive offices) (Zip Code)

(617) 301-9400 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class: Trading symbol(s): Name of each exchange on which registered:

Common Stock, $0.001 par value per shareQTRXThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On January 8, 2026, Quanterix Corporation (“Quanterix”) issued a press release announcing certain executive transitions as described in Item 7.01 below (the “Release”). The Release also discusses Quanterix’s expectations regarding certain financial results for the fiscal year ended December 31, 2025. A copy of the Release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 of this Form 8-K (including the portion of Exhibit 99.1 that discusses Quanterix’s expectations regarding certain financial results for the fiscal year ended December 31, 2025) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 8, 2026, Masoud Toloue, Ph.D., President and Chief Executive Officer of Quanterix Corporation (“Quanterix” or the “Company”), entered into a separation agreement and release with the Company (the “Separation Agreement”), pursuant to which his employment as President and Chief Executive Officer of the Company has ended and he has resigned as a member of the Board of Directors (the “Board”), both effective as of January 19, 2026. In connection with his termination of employment, Dr. Toloue will receive severance benefits consistent with the termination-without-cause provisions of his employment agreement with the Company previously filed with the Securities and Exchange Commission. In addition, the Separation Agreement provides that (i) any outstanding but unvested portions of Dr. Toloue’s equity awards that would have vested on or prior to April 30, 2026 will accelerate and become fully-vested and exercisable on the effective date of Dr. Toloue’s separation, (ii) any such restricted stock units that vest in accordance with the preceding clause will be settled within 60 days following vesting, and (iii) any stock options, to the extent vested, may be exercised on or prior to December 31, 2026. A copy of the Separation Agreement is filed as Exhibit 10.1 and is incorporated herein by reference. Also on January 8, 2026, the Board appointed Everett Cunningham as President and Chief Executive Officer of the Company, effective January 19, 2026. Mr. Cunningham was also appointed to serve on the Board as a Class II director, with a term ending at the 2028 annual meeting of stockholders. Mr. Cunningham has s